嵌合抗原受体
化学
T细胞
信使核糖核酸
细胞生物学
受体
细胞
T细胞受体
抗原
分子生物学
细胞疗法
生物化学
遗传增强
细胞毒性T细胞
免疫疗法
抗原提呈细胞
Jurkat细胞
基因传递
重组DNA
免疫系统
细胞表面受体
抗原处理
转染
脂质体
T淋巴细胞
作者
Qiang Guo,Yu Zhang,Xujia Yang,Qiang Liu,Junlin Sun,Tianyu Luo,Yubo Wang,Zilin Meng,Zijian Pan,Shunhao Wang,Yiran Yang,Yirong Sun,Xuefeng Huang,Ningqiang Gong,Li J
出处
期刊:ACS Nano
[American Chemical Society]
日期:2026-05-14
卷期号:20 (20): 14602-14614
被引量:1
标识
DOI:10.1021/acsnano.6c00706
摘要
The delivery of nucleic acids via lipid nanoparticles (LNPs) to generate chimeric antigen receptor (CAR) T cells in vivo represents a promising therapeutic strategy for a broad spectrum of diseases. Nevertheless, the low efficiency of in vivo gene delivery to T cells remains a major obstacle. In this study, we established a structurally diverse combinatorial library of ionizable lipids based on a β-hydroxy thioether scaffold. From this library, 300 distinct ionizable lipids were synthesized and systematically evaluated for their mRNA delivery efficacy using a luciferase reporter assay in both in vitro and in vivo settings. We identified 113-AA-C8C14 as a leading candidate, which demonstrated a tropism for spleen-specific mRNA delivery. The 113-AA-C8C14 LNPs achieved a 57-fold enhancement in mRNA expression in the spleen compared to a benchmark selective organ-targeting (SORT) LNP formulation. Furthermore, when loaded with mRNA encoding a CD19-specific CAR, the 113-AA-C8C14 LNPs generated 2.7 times more CAR T cells in vivo. This was accompanied by an enhanced T cell response, evidenced by a 2.9-fold and 3.7-fold increase in the secretion of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), respectively. Consequently, this approach led to a 2.3-fold greater inhibition of tumor growth in a mouse model of pancreatic cancer. Our study demonstrates the potential of the 113-AA-C8C14 LNP for in vivo CAR T cell therapy in the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI